#USA #Calgary #Innocan Pharma #LPT-CBD #Chronic Pain Relief

Innocan Pharma Reveals Promising Findings in LPT-CBD Pain Study

Innocan Pharma Corporation, a leader in the pharmaceutical and biotechnology sectors, recently showcased remarkable findings from its research on a liposomal formulation of synthetic cannabidiol (LPT-CBD) aimed at alleviating chronic pain. The study, published in the peer-reviewed journal Frontiers in Pharmacology, titled "Liposomal-synthetic-cannabidiol preliminary translational evidence of efficacy, tolerability and pharmacokinetics following repeated subcutaneous injections in two goats," involved testing the effects of LPT-CBD on two goats suffering from debilitating pain over a 10-month period.

Study Methodology

The researchers conducted subcutaneous injections of LPT-CBD, at a dosage of 5 mg/kg, every six weeks for a total of seven injections per goat. The study’s design included comprehensive monitoring of the goats' health through serial blood sampling to track CBD levels and its metabolites in the bloodstream, alongside evaluations of their hematological and biochemical profiles before and after each injection. Caregivers assessed the efficacy of the treatment weekly, scoring the quality of life (QoL) of the goats based on their pain levels and mobility.

Key Findings

The findings from the study unveiled several significant results:
1. Sustained CBD Plasma Concentrations: The injections maintained steady plasma levels of CBD, demonstrating a slow-release pharmacokinetic profile that could lead to long-lasting pain relief.
2. Excellent Tolerability: Throughout the study, no adverse effects were recorded, indicating a high tolerance for LPT-CBD among the animal subjects.
3. Absence of Liver Enzyme Elevation: Unlike reports of elevated liver enzymes observed in humans who consume oral CBD, the repeated subcutaneous administration of LPT-CBD did not lead to such issues, suggesting a more favorable safety profile.
4. Improved Pain Management: There was notable sustained pain relief and increased mobility in the goats, enhancing their overall quality of life during the study.

Professor Chezy Barenholz, Head of the Advisory Board for Innocan, emphasized, "The study highlights the sustained beneficial effects of LPT-CBD observed over 10 months of repeated administration, showcasing its potential as a treatment for chronic conditions through monthly injections.”

Dr. Eyal Kalo, the Vice President of Research and Development, also added, "This investigation illustrates that LPT-CBD, designed as a non-opioid therapeutic option for chronic pain, does not elevate liver enzymes, thus supporting its long-term safety profile. This contrasts sharply with the oral intake of CBD, which has demonstrated the risk of elevated liver enzyme levels and potential liver damage."

Implications for Future Research

The outcomes of this study provide essential insights that may be translatable to human applications, particularly for individuals suffering from chronic pain who seek safer and effective pain management alternatives. The favorable results in both tolerability and efficacy suggest that the LPT-CBD injections could potentially mirror these benefits in human patients.

Innocan Pharma is progressing to the next phase of clinical research, focusing on how its LPT-CBD formulation can benefit a broader spectrum of patients dealing with chronic pain. As the company continues to innovate in both the pharmaceutical sector—with their CBD-loaded liposome drug delivery platform—and the wellness industry, they remain positioned at the forefront of medical cannabis research and development.

Conclusion

In conclusion, Innocan Pharma’s latest study not only reinforces the efficacy of their LPT-CBD formulation but also highlights its safety and therapeutic potential in treating chronic pain, paving the way for more rigorous trials in human subjects in the near future. The aim is clear: to improve the quality of life for those suffering from chronic conditions without the risks commonly associated with traditional pain medications.